Acuta Capital Partners’s Iovance Biotherapeutics IOVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-153,639
| Closed | -$939K | – | 37 |
|
|
2023
Q1 | $939K | Hold |
153,639
| – | – | 0.69% | 22 |
|
|
2022
Q4 | $982K | Hold |
153,639
| – | – | 0.6% | 26 |
|
|
2022
Q3 | $1.47M | Sell |
153,639
-717
| -0.5% | -$8.27K | 0.63% | 31 |
|
|
2022
Q2 | $1.7M | Buy |
154,356
+35,500
| +30% | +$465K | 0.95% | 29 |
|
|
2022
Q1 | $1.98M | Sell |
118,856
-61,139
| -34% | -$946K | 0.92% | 29 |
|
|
2021
Q4 | $3.44M | Sell |
179,995
-194,500
| -52% | -$4.28M | 1.44% | 25 |
|
|
2021
Q3 | $9.23M | Buy |
374,495
+225,000
| +151% | +$5.3M | 3.26% | 6 |
|
|
2021
Q2 | $3.89M | Buy |
149,495
+51,921
| +53% | +$1.35M | 1.55% | 23 |
|
|
2021
Q1 | $3.09M | Sell |
97,574
-67,226
| -41% | -$2.79M | 1.11% | 34 |
|
|
2020
Q4 | $7.65M | Sell |
164,800
-150,200
| -48% | -$5.96M | 2.08% | 21 |
|
|
2020
Q3 | $10.4M | Sell |
315,000
-275,000
| -47% | -$8.43M | 2.82% | 13 |
|
|
2020
Q2 | $16.2M | Buy |
590,000
+190,500
| +48% | +$6.26M | 4.68% | 4 |
|
|
2020
Q1 | $12M | Sell |
399,500
-257,000
| -39% | -$6.81M | 5.8% | 4 |
|
|
2019
Q4 | $18.2M | Sell |
656,500
-71,000
| -10% | -$1.61M | 4.5% | 7 |
|
|
2019
Q3 | $13.2M | Sell |
727,500
-1,699,201
| -70% | -$37.6M | 9.56% | 2 |
|
|
2019
Q2 | $59.5M | Sell |
2,426,701
-517,500
| -18% | -$7.79M | 21.16% | 1 |
|
|
2019
Q1 | $28M | Sell |
2,944,201
-75,000
| -2% | -$728K | 13.31% | 1 |
|
|
2018
Q4 | $26.7M | Buy |
3,019,201
+796,500
| +36% | +$7.68M | 20.38% | 1 |
|
|
2018
Q3 | $25M | Sell |
2,222,701
-1,802,299
| -45% | -$25.6M | 8.92% | 3 |
|
|
2018
Q2 | $51.5M | Sell |
4,025,000
-235,000
| -6% | -$3.43M | 9.17% | 2 |
|
|
2018
Q1 | $72M | Buy |
4,260,000
+368,000
| +9% | +$5.57M | 11.76% | 2 |
|
|
2017
Q4 | $31.1M | Buy |
3,892,000
+460,191
| +13% | +$3.69M | 5.88% | 4 |
|
|
2017
Q3 | $26.6M | Buy |
3,431,809
+16,765
| +0.5% | +$106K | 4.77% | 6 |
|
|
2017
Q2 | $25.1M | Hold |
3,415,044
| – | – | 7.02% | 5 |
|
|
2017
Q1 | $25.4M | Sell |
3,415,044
-394,900
| -10% | -$2.89M | 6.03% | 5 |
|
|
2016
Q4 | $26.5M | Buy |
3,809,944
+580,028
| +18% | +$3.99M | 9.85% | 2 |
|
|
2016
Q3 | $26.6M | Sell |
3,229,916
-2,500
| -0.1% | -$21.1K | 9.98% | 1 |
|
|
2016
Q2 | $26.2M | Buy |
3,232,416
+732,416
| +29% | +$4.6M | 12.58% | 1 |
|
|
2016
Q1 | $12.7M | Buy |
2,500,000
+585,000
| +31% | +$3.2M | 7.1% | 4 |
|
|
2015
Q4 | $14.8M | Buy |
1,915,000
+600,041
| +46% | +$4.16M | 7.07% | 2 |
|
|
2015
Q3 | $7.57M | Buy |
1,314,959
+428,959
| +48% | +$3.34M | 4.38% | 6 |
|
|
2015
Q2 | $8.13M | Buy |
886,000
+216,804
| +32% | +$2.42M | 5.02% | 5 |
|
|
2015
Q1 | $8.1M | Buy |
+669,196
| New | +$7.54M | 6.83% | 2 |
|
Other funds holding IOVA
PA
MFM
ACA
PAMS
O
Acuta Capital Partners's IOVA Position: Q2 2023 in Review
Acuta Capital Partners sold out of Iovance Biotherapeutics (IOVA) in Q2 2023, closing a stake of 153,639 shares — an estimated $939K sold.
Acuta Capital Partners first reported a position in IOVA in Q1 2015 and held it in 33 quarters. The position peaked at $72M in Q1 2018. 219 funds tracked by Wall St. Rank hold IOVA as of Q2 2023.
- Acuta Capital Partners reported no remaining Iovance Biotherapeutics position as of Q2 2023 after selling out during the quarter.
- Acuta Capital Partners sold 153,639 Iovance Biotherapeutics shares in Q2 2023, an estimated $939K.
- Acuta Capital Partners first reported a position in Iovance Biotherapeutics in Q1 2015 and held it in 33 quarters.
- Acuta Capital Partners's Iovance Biotherapeutics position peaked at $72M in Q1 2018.
- 219 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2023.
Based on Acuta Capital Partners's 13F filing for Q2 2023, filed 14 Aug 2023.